Trial Profile
A PHASE 2, OPEN LABEL STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB (BAVENCIO (REGISTERED)) IN COMBINATION WITH AXITINIB (INLYTA (REGISTERED)) IN PATIENTS WITH ADVANCED OR METASTATIC PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER OR TREATMENT NAIVE CISPLATIN-INELIGIBLE UROTHELIAL CANCER JAVELIN MEDLEY VEGF
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary)
- Indications Bladder cancer; Carcinoma; Non-small cell lung cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms Javelin Medley VEGF
- Sponsors Pfizer
- 03 May 2023 This trial has been completed in Poland (End Date: 09 Feb 2023), according to European Clinical Trials Database record.
- 22 Mar 2023 Status changed from active, no longer recruiting to discontinued.
- 02 Feb 2023 Planned End Date changed from 28 Dec 2022 to 14 Feb 2023.